BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 32668215)

  • 1. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.
    Wan J; Xing S; Ding L; Wang Y; Gu C; Wu Y; Rong B; Li C; Wang S; Chen K; He C; Zhu D; Yuan S; Qiu C; Zhao C; Nie L; Gao Z; Jiao J; Zhang X; Wang X; Ying T; Wang H; Xie Y; Lu Y; Xu J; Lan F
    Cell Rep; 2020 Jul; 32(3):107918. PubMed ID: 32668215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin fragment F(ab')
    Pan X; Zhou P; Fan T; Wu Y; Zhang J; Shi X; Shang W; Fang L; Jiang X; Shi J; Sun Y; Zhao S; Gong R; Chen Z; Xiao G
    Antiviral Res; 2020 Oct; 182():104868. PubMed ID: 32659292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
    Brouwer PJM; Caniels TG; van der Straten K; Snitselaar JL; Aldon Y; Bangaru S; Torres JL; Okba NMA; Claireaux M; Kerster G; Bentlage AEH; van Haaren MM; Guerra D; Burger JA; Schermer EE; Verheul KD; van der Velde N; van der Kooi A; van Schooten J; van Breemen MJ; Bijl TPL; Sliepen K; Aartse A; Derking R; Bontjer I; Kootstra NA; Wiersinga WJ; Vidarsson G; Haagmans BL; Ward AB; de Bree GJ; Sanders RW; van Gils MJ
    Science; 2020 Aug; 369(6504):643-650. PubMed ID: 32540902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Tai W; Zhang X; He Y; Jiang S; Du L
    Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
    Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI
    Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
    Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.
    Li Y; Lai DY; Zhang HN; Jiang HW; Tian X; Ma ML; Qi H; Meng QF; Guo SJ; Wu Y; Wang W; Yang X; Shi DW; Dai JB; Ying T; Zhou J; Tao SC
    Cell Mol Immunol; 2020 Oct; 17(10):1095-1097. PubMed ID: 32895485
    [No Abstract]   [Full Text] [Related]  

  • 14. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
    Du S; Cao Y; Zhu Q; Yu P; Qi F; Wang G; Du X; Bao L; Deng W; Zhu H; Liu J; Nie J; Zheng Y; Liang H; Liu R; Gong S; Xu H; Yisimayi A; Lv Q; Wang B; He R; Han Y; Zhao W; Bai Y; Qu Y; Gao X; Ji C; Wang Q; Gao N; Huang W; Wang Y; Xie XS; Su XD; Xiao J; Qin C
    Cell; 2020 Nov; 183(4):1013-1023.e13. PubMed ID: 32970990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein.
    Wrobel AG; Benton DJ; Hussain S; Harvey R; Martin SR; Roustan C; Rosenthal PB; Skehel JJ; Gamblin SJ
    Nat Commun; 2020 Oct; 11(1):5337. PubMed ID: 33087721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.